Macrogenics MGNX
NASDAQ MGNX
$4.40 +0.15 (+3.53%)
At close: Sep 4, 2026 · 4:00 PM EDT

Macrogenics (MGNX) Curent Deferred Tax Liability (2014)

Macrogenics (MGNX) posted quarterly Curent Deferred Tax Liability of $1.6 million for Q4 2014.

Analysis

Macrogenics (MGNX) Curent Deferred Tax Liability (2014) Analysis & Trends

Macrogenics (MGNX) has reported Curent Deferred Tax Liability for 1 consecutive years, with $1.6 million the latest figure, recorded in Q4 2014.

  • In Q4 2014, Curent Deferred Tax Liability changed N/A year-over-year to $1.6 million; the TTM figure through Dec 2014 stood at $1.6 million (changed N/A YoY), while the FY2014 annual figure was $1.6 million, changed N/A from the prior year.
  • Curent Deferred Tax Liability steadied at $1.6 million in Q4 2014 per MGNX's latest filing.
  • Across five years, Curent Deferred Tax Liability topped out at $1.6 million in Q4 2014 and bottomed at $1.6 million in Q4 2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax Liability (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Macrogenics 284.90 Mn 171.00 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 1.60 Mn